Moxonidine Teva Uk

Moxonidine, the active ingredient in Moxonidine Teva Uk, is an imidazoline receptor agonist presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adults with hypertension.

GNH USA supplies Moxonidine Teva Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. With a focus on regulatory compliance and product integrity, GNH USA ensures consistent availability of this antihypertensive agent across diverse markets.

Moxonidine is used to manage hypertension by targeting central sympathetic pathways.

Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. Resistant hypertension: provides additional blood pressure control when standard therapies are insufficient. Hypertension with sympathetic overactivity: attenuates central sympathetic tone to improve blood pressure regulation.

Moxonidine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dry mouth: sensation of oral dryness. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: light‑headedness, especially upon standing. - Headache: mild to moderate cranial pain. - Nausea: upset stomach with urge to vomit.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Bradycardia: abnormally slow heart rate. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing Moxonidine, clinicians should observe several precautionary measures to ensure safe use.

Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. Renal impairment: adjust dose or use with caution in patients with reduced kidney function. Hepatic impairment: consider dose reduction in those with liver disease. Elderly patients: start at low dose and monitor for dizziness or falls. Discontinuation: avoid abrupt cessation; taper gradually to prevent rebound hypertension. Store at room temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Moxonidine can interact with other medicines, altering its antihypertensive effect or safety profile.

Major Interactions (Avoid): - Clonidine: additive central hypotensive effect may cause severe blood pressure drop. - Other imidazoline agonists (e.g., guanfacine): combined use can lead to excessive hypotension. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase plasma concentrations of moxonidine.

Moderate Interactions (Monitor Closely): - Diuretics: concurrent use may enhance antihypertensive response, requiring blood pressure monitoring. - ACE inhibitors or ARBs: combined therapy can increase risk of hypotension. - NSAIDs: may attenuate the blood‑pressure‑lowering effect of moxonidine. - Beta‑blockers: additive effect on heart rate and blood pressure, warranting dose adjustments.